- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07942025
90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Efficacy and Long-Term Outcomes of Yttrium-90 Treatment as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study
This multicenter observational study will evaluate long-term outcomes in patients with initially unresectable hepatocellular carcinoma who undergo curative-intent hepatectomy after conversion therapy. The conversion therapy is based on either yttrium-90 selective internal radiation therapy or transarterial chemoembolization. The study includes a retrospective cohort and a prospective observational cohort. The primary outcome is recurrence-free survival after surgery. Overall survival, postoperative pathological features, and perioperative outcomes will also be compared between the two groups.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This study includes both retrospective and prospective components. The retrospective cohort will include eligible patients who previously underwent curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. The prospective observational cohort will consecutively enroll eligible patients after curative-intent hepatectomy and follow them prospectively for postoperative outcomes.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Zheyu Zhou
- Numero di telefono: +86 18851092739
- Email: zzys02910@btch.edu.cn
Luoghi di studio
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 102218
- Beijing Tsinghua Changgung Hospital
-
Contatto:
- Lin Zhang
- Numero di telefono: +86 15699793366
- Email: zla02285@btch.edu.cn
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Cina, 400038
- Southwest Hospital, Army Medical University
-
Contatto:
- Hui Zhang
- Numero di telefono: +86 02368754000
- Email: 13637912611@163.com
-
-
Fujian
-
Fuzhou, Fujian, Cina, 350025
- Mengchao Hepatobiliary Hospital of Fujian Medical University
-
Contatto:
- Wuhua Guo
- Numero di telefono: +86 059188110232
- Email: guowuhua@aliyun.com
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510630
- The First Affiliated Hospital of Jinan University
-
Contatto:
- Chengzhi Li
- Numero di telefono: +86 02038688888
- Email: lichengzhi@jnu.edu.cn
-
-
Liaoning
-
Shenyang, Liaoning, Cina, 110001
- The First Hospital of China Medical University
-
Contatto:
- Haibo Shao
- Numero di telefono: +86 02483283333
- Email: haiboshao@aliyun.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Cina, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Contatto:
- Xin Zheng
- Numero di telefono: +86 02985323112
- Email: xin.zheng.xjtu@gmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The study population consists of patients with initially unresectable HCC treated at participating centers who undergo curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. All consecutive patients meeting the predefined eligibility criteria will be included. Patients identified from historical records will form the retrospective cohort, while patients enrolled after study initiation will form the prospective observational cohort.
Descrizione
Inclusion Criteria:
- Initially unresectable primary liver cancer.
- Underwent curative-intent hepatectomy following conversion therapy based on 90Y-SIRT or TACE.
- Postoperative histopathological examination confirmed HCC.
Exclusion Criteria:
- Received conversion therapy based on other locoregional treatments, such as hepatic arterial infusion chemotherapy (HAIC) or external beam radiotherapy (EBRT).
- Presence of extrahepatic metastasis prior to curative-intent hepatectomy.
- Postoperative histopathological diagnosis of intrahepatic cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA).
- Failure to achieve R0 resection.
- Incomplete clinical data.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: OTHER
Coorti e interventi
Gruppo / Coorte |
|---|
|
90Y-SIRT-Based Conversion Therapy Group
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on yttrium-90 selective internal radiation therapy (90Y-SIRT) and subsequently underwent curative-intent hepatectomy after being deemed resectable. |
|
TACE-Based Conversion Therapy Group
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on transarterial chemoembolization (TACE) and subsequently underwent curative-intent hepatectomy after being deemed resectable. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Postoperative recurrence-free survival (RFS)
Lasso di tempo: From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
|
From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Postoperative overall survival (OS)
Lasso di tempo: From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
|
From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
|
|
|
Pathological complete response (pCR) rate
Lasso di tempo: Immediately after curative-intent hepatectomy.
|
pCR is defined as the absence of residual viable tumor cells in the resected specimens. The pCR rate is calculated as the proportion of patients achieving pCR among all patients with evaluable postoperative histopathological assessments. |
Immediately after curative-intent hepatectomy.
|
|
Major pathological response (MPR) rate
Lasso di tempo: Immediately after curative-intent hepatectomy.
|
MPR is defined as ≤10% residual viable tumor cells in the resected specimens. The MPR rate is calculated as the proportion of patients achieving MPR among all patients with evaluable postoperative histopathological assessments. |
Immediately after curative-intent hepatectomy.
|
|
Microvascular invasion (MVI) positivity rate
Lasso di tempo: Immediately after curative-intent hepatectomy.
|
Immediately after curative-intent hepatectomy.
|
|
|
Satellite nodule positivity rate
Lasso di tempo: Immediately after curative-intent hepatectomy.
|
Immediately after curative-intent hepatectomy.
|
|
|
Postoperative complication rate
Lasso di tempo: Perioperatively, from curative-intent hepatectomy through hospital discharge.
|
The occurrence and type of postoperative complications will be recorded, and their severity will be graded according to the Clavien-Dindo classification. Bile leakage and post-hepatectomy liver failure (PHLF) will also be graded according to the ISGLS criteria. |
Perioperatively, from curative-intent hepatectomy through hospital discharge.
|
Altre misure di risultato
Misura del risultato |
Lasso di tempo |
|---|---|
|
Percentage change in tumor markers
Lasso di tempo: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
|
Percentage change in maximum tumor diameter
Lasso di tempo: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Lin Zhang, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- KX26-0904-0317
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
De-identified IPD underlying the published results may be made available upon reasonable request after publication, subject to approval by the principal investigator and applicable ethical and institutional requirements.
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .